Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : Credit Suisse gives a Buy rating

10/12/2020 | 01:50pm EST

In a research note published by Trung Huynh, Credit Suisse advises its customers to buy the stock. The target price is unchanged and still at DKK 470.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG 0.51% 11.715 Delayed Quote.-10.61%
NOVO NORDISK A/S 1.09% 419.25 Delayed Quote.8.43%
All news about NOVO NORDISK A/S
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
AQ
11/12NOVO NORDISK A/S : set to acquire Emisphere for $1.8 billion
AQ
11/09NOVO NORDISK A/S : to acquire Emisphere Technologies and obtain ownership of the..
AQ
11/09NOVO NORDISK : UBS reiterates its Neutral rating
MD
More news
Financials
Sales 2020 127 B 20 492 M 20 492 M
Net income 2020 42 174 M 6 783 M 6 783 M
Net cash 2020 8 472 M 1 363 M 1 363 M
P/E ratio 2020 23,2x
Yield 2020 2,15%
Capitalization 971 B 156 B 156 B
EV / Sales 2020 7,55x
EV / Sales 2021 7,09x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 419,25 DKK
Spread / Highest target 30,0%
Spread / Average Target 4,88%
Spread / Lowest Target -30,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S8.43%155 954
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440